Angie You and Volker Schellenberger, Amunix

Pounc­ing on next-gen I/O play, Sanofi ac­quires Amu­nix for $1B+ and picks up 'u­ni­ver­sal mask' tech

Sanofi is crash­ing the year-end M&A par­ty with a deal of its own.

Im­muno-on­col­o­gy is the name of the game as it swal­lows Moun­tain View, CA-based Amu­nix for $1 bil­lion up­front and up to $225 mil­lion in biobucks, tag­ging a suite of T cell en­gagers and cy­tokine ther­a­pies as well as a tech plat­form for mak­ing “con­di­tion­al­ly ac­ti­vat­ed bi­o­log­ics.”

“The Amu­nix tech­nol­o­gy plat­form uti­lizes a next gen­er­a­tion smart bi­o­log­ics ap­proach to pre­cise­ly tai­lor-de­liv­er med­i­cines to be­come ac­tive on­ly in tu­mor tis­sues while spar­ing nor­mal tis­sues,” said Sanofi R&D chief John Reed, “thus bring­ing the promise of more ef­fec­tive and safer treat­ment op­tions for can­cer pa­tients.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.